Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979403414> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2979403414 endingPage "vi128" @default.
- W2979403414 startingPage "vi127" @default.
- W2979403414 abstract "Abstract Background The warfarin is known to enhance its activity by interaction with fluoropyrimidine. On the other hands, direct oral anticoagulants (DOACs) have several advantages compared with warfarin such as the unnecessity of dose monitoring and their few drug interactions. Therefore, the aim of this study is to assess the dose intensity and safety of fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with DOACs or warfarin. Methods Between January 2006 to June 2018, a total of 1,413 patients with esophageal, gastric, colorectal, and pancreatic cancer received fluoropyrimidine-based chemotherapy at two institutions. Among all patients, 49 patients with anticoagulant therapy were enrolled in this study. They were further divided into the warfarin group (27 patients) and the DOACs group (22 patients). We retrospectively analyzed their Relative Dose Intensity (RDI) of fluoropyrimidine, Time in Therapeutic Range (TTR) of warfarin, and bleeding or thrombosis events. Results In the warfarin group, the median RDI of fluoropyrimidne and TTR of warfarin was 80.0% (0-100%) and 37.5% (0-100%), respectively. The proportion of patients with prolonged PT-NR values (cut off value of 3.00) was 51.9% (14/27). In the DOACs group, the median RDI was 72.9% (0-100%). There was no significant difference in RDI (p = 0.88), although TTR of warfarin was relatively low. The bleeding or thrombosis events occurred only in the warfarin group (3.7% and 7.4%, respectively). Conclusions This study showed the RDI of fluoropyrimidine in the DOACs group was sufficient compared with the warfarin group. However, major bleeding and thrombosis events, which seemed to be related with low TTR of warfarin, occurred only in the warfarin group. These data may suggest that DOACs are recommended as better anti-coagulation agents than warfarin during chemotherapies using fluoropyrimidine for gastrointestinal cancer." @default.
- W2979403414 created "2019-10-18" @default.
- W2979403414 creator A5013179673 @default.
- W2979403414 creator A5014047853 @default.
- W2979403414 creator A5015023308 @default.
- W2979403414 creator A5017951288 @default.
- W2979403414 creator A5024836248 @default.
- W2979403414 creator A5041698698 @default.
- W2979403414 creator A5042401726 @default.
- W2979403414 creator A5056456991 @default.
- W2979403414 creator A5065692477 @default.
- W2979403414 creator A5070164821 @default.
- W2979403414 creator A5076120991 @default.
- W2979403414 creator A5078310459 @default.
- W2979403414 creator A5087388222 @default.
- W2979403414 date "2019-10-01" @default.
- W2979403414 modified "2023-09-27" @default.
- W2979403414 title "Fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with direct oral anticoagulants or warfarin" @default.
- W2979403414 doi "https://doi.org/10.1093/annonc/mdz343.045" @default.
- W2979403414 hasPublicationYear "2019" @default.
- W2979403414 type Work @default.
- W2979403414 sameAs 2979403414 @default.
- W2979403414 citedByCount "0" @default.
- W2979403414 crossrefType "journal-article" @default.
- W2979403414 hasAuthorship W2979403414A5013179673 @default.
- W2979403414 hasAuthorship W2979403414A5014047853 @default.
- W2979403414 hasAuthorship W2979403414A5015023308 @default.
- W2979403414 hasAuthorship W2979403414A5017951288 @default.
- W2979403414 hasAuthorship W2979403414A5024836248 @default.
- W2979403414 hasAuthorship W2979403414A5041698698 @default.
- W2979403414 hasAuthorship W2979403414A5042401726 @default.
- W2979403414 hasAuthorship W2979403414A5056456991 @default.
- W2979403414 hasAuthorship W2979403414A5065692477 @default.
- W2979403414 hasAuthorship W2979403414A5070164821 @default.
- W2979403414 hasAuthorship W2979403414A5076120991 @default.
- W2979403414 hasAuthorship W2979403414A5078310459 @default.
- W2979403414 hasAuthorship W2979403414A5087388222 @default.
- W2979403414 hasBestOaLocation W29794034141 @default.
- W2979403414 hasConcept C121608353 @default.
- W2979403414 hasConcept C126322002 @default.
- W2979403414 hasConcept C143998085 @default.
- W2979403414 hasConcept C2776301958 @default.
- W2979403414 hasConcept C2776694085 @default.
- W2979403414 hasConcept C2779161974 @default.
- W2979403414 hasConcept C2983288658 @default.
- W2979403414 hasConcept C526805850 @default.
- W2979403414 hasConcept C542804219 @default.
- W2979403414 hasConcept C71924100 @default.
- W2979403414 hasConceptScore W2979403414C121608353 @default.
- W2979403414 hasConceptScore W2979403414C126322002 @default.
- W2979403414 hasConceptScore W2979403414C143998085 @default.
- W2979403414 hasConceptScore W2979403414C2776301958 @default.
- W2979403414 hasConceptScore W2979403414C2776694085 @default.
- W2979403414 hasConceptScore W2979403414C2779161974 @default.
- W2979403414 hasConceptScore W2979403414C2983288658 @default.
- W2979403414 hasConceptScore W2979403414C526805850 @default.
- W2979403414 hasConceptScore W2979403414C542804219 @default.
- W2979403414 hasConceptScore W2979403414C71924100 @default.
- W2979403414 hasLocation W29794034141 @default.
- W2979403414 hasOpenAccess W2979403414 @default.
- W2979403414 hasPrimaryLocation W29794034141 @default.
- W2979403414 hasRelatedWork W1619421778 @default.
- W2979403414 hasRelatedWork W1973143596 @default.
- W2979403414 hasRelatedWork W1984286416 @default.
- W2979403414 hasRelatedWork W2165594237 @default.
- W2979403414 hasRelatedWork W2354397679 @default.
- W2979403414 hasRelatedWork W2366672056 @default.
- W2979403414 hasRelatedWork W2439591364 @default.
- W2979403414 hasRelatedWork W2917422071 @default.
- W2979403414 hasRelatedWork W4234108101 @default.
- W2979403414 hasRelatedWork W191440478 @default.
- W2979403414 hasVolume "30" @default.
- W2979403414 isParatext "false" @default.
- W2979403414 isRetracted "false" @default.
- W2979403414 magId "2979403414" @default.
- W2979403414 workType "article" @default.